Tracer library / [166Ho]Ho-166-PLLA

[166Ho]Ho-166-PLLA

Also written as Ho-166-PLLA

Radionuclide: Ho-166 t½ 1609.8 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 0

Hepatobiliary and pancreatic cancer Neuroendocrine neoplasms Dosimetry and biodistribution studies

What it is

Compound class: Holmium-166 microspheres (poly-L-lactic acid, PLLA)
Target / mechanism: Selective internal radiotherapy (transarterial radioembolization) via microsphere embolization delivering beta radiation to liver tumors PMID 38564100
Clinical application: Selective internal radiotherapy (SIRT) of liver tumors/metastases, including combination with PRRT for neuroendocrine liver metastases PMID 40302310
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Blood and urine analyses after radioembolization of liver malignancies with [166Ho]Ho-acetylacetonate-poly(l-lactic acid) microspheres.
2019 · Nucl Med Biol · Clinical study · Phase II

Need this precursor?We can point you to suppliers for [166Ho]Ho-166-PLLA, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.